Lead Product(s) : GSK4382276A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Doses First Participant in Phase 2 Seasonal Influenza Study with GSK
Details : Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.
Product Name : GSK4382276A
Product Type : Vaccine
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : GSK4382276A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CV0701
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Announces Positive Phase 2 Interim Data for COVID-19 Vaccine with GSK
Details : CV0701 is a biovalent vaccine candidate, which encodes the spike protein of the omicron BA.4-5 variant and it is under phase 2 clinical development for the treatment of Covid-19 infection.
Product Name : CV0701
Product Type : Vaccine
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : CV0701
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Berlin Cures Achieves Milestone in BC 007 Phase II Trial for Long COVID
Details : BC 007 (rovunaptabin) is a novel therapeutic candidate using DNA-based aptamers to target and neutralize functional autoantibodies against G-protein coupled receptors for Long COVID.
Product Name : BC 007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSK4382276A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Announces Positive Phase 2 Interim Data from Influenza Vaccine Program with GSK
Details : Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.
Product Name : GSK4382276A
Product Type : Vaccine
Upfront Cash : Inapplicable
April 04, 2024
Lead Product(s) : GSK4382276A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Berlin Cures' BC 007 Targets Long COVID with Over 50% Patient Recruitment
Details : BC 007 is a DNA-based aptamer designed to specifically target and neutralize functional autoantibodies (fAABs) directed against G-protein coupled receptors. It is being evaluated for Long Covid.
Product Name : BC 007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Rovunaptabin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSK4382276A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Biogen
Deal Size : $1,556.0 million
Deal Type : Licensing Agreement
GSK buys full rights to make COVID, influenza vaccines from CureVac
Details : Through a licensing agreement, GSK will acquire full rights from Curevac of Flu mRNA (GSK4382276) to develop, manufacture, and commercialize globally mRNA candidate vaccines for influenza.
Product Name : GSK4382276A
Product Type : Vaccine
Upfront Cash : $429.2 million
March 07, 2024
Lead Product(s) : GSK4382276A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Biogen
Deal Size : $1,556.0 million
Deal Type : Licensing Agreement
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Biocure Technology
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the acquisition, Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses, including ATR-002 (zapnometinib), a first-in-class, host-targeting agent that aims to inhibit viral r...
Product Name : ATR-002
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Biocure Technology
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Swiss TPH
Deal Size : Undisclosed
Deal Type : Partnership
Bayer and Swiss TPH to Develop Treatment Against Soil-Transmitted Helminths
Details : The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.
Product Name : BAY 44-4400
Product Type : Peptide
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Swiss TPH
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : CV0601
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant and is being developed in collaboration with GSK
Product Name : CV0601
Product Type : Vaccine
Upfront Cash : Inapplicable
January 08, 2023
Lead Product(s) : CV0601
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
Details : RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support at the time of screening or randomization.
Product Name : ATR-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable